$216 Million is the total value of Prosight Management, LP's 42 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $27,457,000 | +107.2% | 175,738 | +51.8% | 12.69% | +101.3% |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $15,237,000 | +486.5% | 2,023,441 | +199.1% | 7.04% | +469.6% |
| PRTA | Buy | PROTHENA CORP PLC | $13,105,000 | +140.6% | 1,091,202 | +100.1% | 6.06% | +133.7% |
| CUE | Buy | CUE BIOPHARMA INC | $11,341,000 | +6.1% | 906,569 | +27.7% | 5.24% | +3.1% |
| EHC | Buy | ENCOMPASS HEALTH CORP | $9,451,000 | +34.8% | 114,300 | +5.9% | 4.37% | +30.9% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $6,830,000 | – | 28,900 | +100.0% | 3.16% | – |
| ALBO | Buy | ALBIREO PHARMA INC | $6,556,000 | +60.4% | 174,791 | +42.7% | 3.03% | +55.8% |
| Buy | ALEXION PHARMACEUTICALS INCcall | $6,250,000 | +60.6% | 40,000 | +17.6% | 2.89% | +56.0% | |
| CARA | Buy | CARA THERAPEUTICS INC | $4,449,000 | +100.2% | 294,041 | +68.4% | 2.06% | +94.5% |
| MTCR | Buy | METACRINE INC | $4,428,000 | -16.4% | 563,303 | +8.6% | 2.05% | -18.8% |
| INOV | New | INOVALON HLDGS INC | $4,195,000 | – | 230,877 | +100.0% | 1.94% | – |
| New | TWIST BIOSCIENCE CORPput | $3,532,000 | – | 25,000 | +100.0% | 1.63% | – | |
| MGLN | New | MAGELLAN HEALTH INC | $3,145,000 | – | 37,969 | +100.0% | 1.45% | – |
| New | PROTHENA CORP PLCcall | $2,104,000 | – | 175,200 | +100.0% | 0.97% | – | |
| ADMA | Buy | ADMA BIOLOGICS INC | $1,722,000 | +34.5% | 883,214 | +65.0% | 0.80% | +30.7% |
| New | VERACYTE INCput | $1,713,000 | – | 35,000 | +100.0% | 0.79% | – | |
| New | SPDR SER TRput | $1,408,000 | – | 10,000 | +100.0% | 0.65% | – | |
| New | ARENA PHARMACEUTICALS INCcall | $1,383,000 | – | 18,000 | +100.0% | 0.64% | – | |
| PRQR | New | PROQR THRAPEUTICS N V | $1,071,000 | – | 255,000 | +100.0% | 0.50% | – |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $1,052,000 | – | 60,250 | +100.0% | 0.49% | – |
| New | ARK ETF TRput | $933,000 | – | 10,000 | +100.0% | 0.43% | – | |
| New | BEAM THERAPEUTICS INCput | $816,000 | – | 10,000 | +100.0% | 0.38% | – | |
| New | AKUMIN INC | $675,000 | – | 224,273 | +100.0% | 0.31% | – | |
| LHCG | New | LHC GROUP INC | $586,000 | – | 2,746 | +100.0% | 0.27% | – |
| MRNA | New | MODERNA INC | $18,000 | – | 174 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.